Nanofibres Developed That Improve the Attachment of Bone Implants
In future, it may be possible to use nanofibres to improve the attachment of bone implants, or the fibres may be used directly to scaffold bone regeneration. This would aid the healing of fractures and may enable the care of osteoporosis.
In his doctoral research, Jani Holopainen of the Department of Chemistry at the University of Helsinki has developed processes for fibrous and thin-film biomaterials that can be used as scaffolding for bone regeneration and in other bone implants. He also studied the apparatus used for nanofiber production.
At best, bone-reforming scaffolds that regenerate at the same rate as bones could be used as implants. The scaffolds activate the bone cells to generate new bone that slowly replaces the disintegrating scaffold and the implant exits the body naturally without separate removal surgery. Holopainen selected hydroxyapatite, the main component of the bone mineral, as the focus of his research; this is why the synthetic hydroxyapatite structures he has developed are very compatible with bone.
Holopainen developed the electrospinning apparatus for producing hydroxyapatite fibres, and a new kind of needleless twisted wire electrospinning setup which is more productive than the generally known electrospinning method. The prototypes for the equipment used in the research were manufactured at the Department of Chemistry at the University of Helsinki. The equipment will have to be developed further in order to enhance production to an industrial scale.
This promising method still has a long way to go before it will become a real medical application, though cellular tests have already been made, says Professor Mikko Ritala of the Department of Chemistry and the Atomic Layer Deposition centre of excellence at the University of Helsinki.
This article has been republished from materials provided by the University of Helsinki. Note: material may have been edited for length and content. For further information, please contact the cited source.
Combating Cancer by Targeting Sugar ReceptorsNews
Globally, cancer is the second leading cause of death, also because the efficiency of chemotherapeutics is inadequate due to poor delivery to the tumor. Prof. Olivia Merkel and her team develop targeted nanocarrier systems to increase the delivery rates of therapeutic formulations and their specific uptake into the target cells.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018